RE:RE:RE:RE:RE:RE:RE:RE:So Just wanted to correct a false statement regarding the share dilution over the last 8 years. The shares outstanding for TLT were 40 million at year end 2010. So the share dilution since 2010 has been 95 million shares and not the 55 million shares number I have seen repeated many times.
CAInPlap ... Again, do I really care about you!
Even if you participated in the last 2 pps, just sell and go invest elsewhere if you doubt that TLT won't be able to finance their clinical trials responsably. You're just another of these insecure armchair quarterbacks that cannot appreciate everything this management has done so far to deliver so much innovation at so little dilution so far for your own investment. 55M TSO shares between 2010 and today (from 80M to 135M). Go compare and come back to us, just for fun!
Your issue regarding the financing, we read them on any TMX-V boards. If you think that TLT will spell in advance what's coming up, then you're a little delusional investor. TLT's reality is no different than any other biotechs or company; at key moment, they cannot disclose everything you'd like to know. Especially when they battle against big pharmas. Competition is fierce so they have to hold their cards very close to their chest to avoid that your investment going down the drain. Someone, with the OSC investigation, tried to harm/disrupt/derail TLT's goal. Funny that you even don't recall that basic event!
So who are you to tell me what to post when I put links in my posts, that you tell me that you learned absolutely nothing from any of my posts and that I see absolutely no contribution from you on this board. Prove me otherwise if you have sounded posts. I'll be glad to read them and retract myself.
Hiligther bugs you? Poor you. Then put your sunglasses on. Thought hilighter was there to focus on key excerpts, to stress key elements, when one doesn't have the time to read everything! And it's among the biggest consumer product sold across the world. So looks like you're late on the parade.